InMed Shares Update to Biosynthesis Program Development

InMed Pharmaceuticals (CSE:IN; OTCQB:IMLFF) shared an update to investors on the advancements of their proprietary technology for the microbial biosynthesis of cannabinoids.
As quoted in the press release:

InMed has successfully demonstrated that it can selectively produce all four “gateway” cannabinoids using genetically engineered microorganisms. These molecules can be functionalized further to produce any of the 90+ “downstream” cannabinoids found naturally in the cannabis plant. The company is actively employing this production chassis to synthesize compounds for its pharmaceutical research programs.
Eric A. Adams, President & CEO states, “Successful scale-up and commercialization of the biosynthesis process for cannabinoid production is a top priority for InMed.

Click here to read the full press release.

Source: www.newswire.ca